"Two novel products for the treatment of non-small-cell lung cancer (NSCLC) have been recommended for approval in Europe: osimertinib (Tagrisso, AstraZeneca) and necitumumab (Portrazza, Eli Lilly).
None.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/4/2017
Additional Xalkori Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.